BAYRY BAYER AG
- 7.830
- +0.060+0.77%
- 7.805
- -0.026-0.33%
BAYER AG News
Bayer Highlights Detailed Data From Twin Late-Stage Trials On Experimental Menopause Candidate, Seeks Regulatory Approval
Pharma Stock Roundup: BAYRY's Q1 Earnings, JNJ's New Buyout, Pipeline Updates
Bayer Menopause Drug Shows Positive Result in Late-Stage Trials
Bayer AG said a positive outcome from twin late-stage trials on a promising experimental menopause treatment will help it seek regulatory approval.
Bayer Hot Flashes Treatment Elinzanetant Meets Goals in Late-stage Trials
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
On Sunday, Pfizer (NYSE:PFE) and AstraZeneca Plc (NASDAQ:AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France, j
Bayer Sees Rise of More Innovative Drugs
With China offering a constantly improving business environment, deeper industrial collaboration and more innovation, multinational corporations in the pharmaceutical industry and Chinese startups will have more growth opportunities, thereby bringing more innovative drugs to the market, said an executive of German life sciences company Bayer.
Earnings Call Summary | BAYER AG(BAYZF.US) Q1 2024 Earnings Conference
The following is a summary of the Bayer AG (BAYZF) Q1 2024 Earnings Call Transcript:Financial Performance:Bayer reported Q1 sales of €13.8 billion, slightly lower than the previous year.Core earnings
Bayer Cut 1500 Jobs in Q1
Bayer (BAYRY.US): The 2024 Q1 financial report achieved revenue of US$14.95 billion, with an earlier value of US$15.443 billion, with an expected value of US$15.91 billion; earnings per share were US$0.77, the previous value was US$0.79, and the expected
Bayer (BAYRY.US): The 2024 Q1 financial report achieved revenue of US$14.95 billion, with an earlier value of US$15.443 billion, with an expected value of US$15.91 billion; earnings per share were US$0.77, the previous value was US$0.79, and the expected value was US$0.42.
Bayer Earnings Show Progression on Turnaround Strategy -- Market Talk
1100 GMT - Bayer's earnings beat and its backed full-year guidance show progression on its turnaround strategy, Barclays analysts say in a note. The German pharmaceutical and agricultural company's Eb
Express News | Bayer CEO: Bayer laid off 1,500 employees in the first quarter.
German Drugmaker Bayer Posts Decline in Q1 Income, Net Sales
Bayer (BAYN.F) said Tuesday its income and net sales fell year over year in the first quarter.
Bayer Backs 2024 Currency-Adjusted Outlook
Bayer Backs 2024 Currency-Adjusted Outlook
Bayer: Analysts Saw 1Q Sales at EUR14.08B
Bayer: Analysts Saw 1Q Sales at EUR14.08B
Bayer 1Q Ebitda Before Special Items EUR4.41B
Bayer 1Q Ebitda Before Special Items EUR4.41B
Bayer 1Q Net Pft EUR2B
Bayer 1Q Net Pft EUR2B
Express News | Bayer's adjusted EBITDA for the first quarter was 4.41 billion euros, estimated at 4.2 billion euros; Bayer's sales for the first quarter were 13.77 billion euros, estimated at 14.01 billion euros.
From Hype To Reality, AI Reshapes Pharmaceutical Industry Across Drug Discovery To Marketing - Stocks To Watch
Pharmaceutical companies have been at the forefront of artificial intelligence for quite some time. Researchers have been using advanced AI models to understand disease mechanisms even before the rece
Stocks to Watch Next Week: Burberry, Vodafone, BT and Walmart
Elanco Surges on Q1 Beat, Anticipated Product Launches
Analysis
Price Target
No Data
